OAS Logo

Log in

Recent Posts from the OASIS Newsletter

OASIS Newsetter Winter 2024

17 Jan 2024 3:54 PM | Jennifer Schlabach (Administrator)

Winter 2024 Issue

Happy New Year OAS Members!

We are eagerly looking forward to an exciting 2024, starting with our Annual Meeting February 9-10 in Houston with the addition of an Ophthalmic Block Workshop on February 11th.

Hot Topics and Speakers for Next Month!

-International Mission Work with Ophthalmology
David Markoff, MD

-Pediatric Anesthesia- Clinical Tools for the Everyday Practitioner
Neil Masters, MD

-International Speakers

Adrian Kwa, MD, Nottingham University Hospitals NHS Trust, UK

Iosifina Giannakikou, MD, Hygeia Hospital, Greece

Lakshmi Prasanna Srinivasan, MD, Sankara Nethralaya, India

-Incision Free eye Blocks- American Approach                      
Howard Palte, MD, University of Miami

And more!

Read about all OAS speakers here!

Full Agenda

Register Today!

For the OAS to continue to provide these essential Educational & Networking programs, we need everyone’s help in promoting the value of the OAS to our colleagues.

Please feel free to share the meeting information with your colleagues that may not be on our distribution list. 

Hope to see everyone in Houston next month!

Workshop Overview: 

Orbital Anatomy
Randy Harvey, BS, RRT, APRN, CRNA, FAANA, Orbital Compliance Group

Ophthalmic blocks
Randy Harvey, BS, RRT, APRN, CRNA, FAANA, Orbital Compliance Group

Simulation Training

Randy Harvey, BS, RRT, APRN, CRNA, FAANA, Orbital Compliance Group

Adrian Kwa, MD, Nottingham University Hospitals NHS Trust, UK

Matthew Springer, DNAP, CRNA, Lincoln Surgical Hospital

Whether you are an anesthesiologist, CRNA, ophthalmologist, nurse, resident or student, there is something for everyone at the OAS Annual Scientific Meeting.

Register Today!

ADD on the fun

Puttshack is an upscale, tech-infused mini golf experience that pairs modern technology with crazy courses and trendy vibes for an experience of teamwork and fun. 

Join your fellow attendees at this fun evening event on Saturday, evening 6:30 - 8:30 PM.

Register with your conference registration.


RENEW NOW and benefit from reduced registration at the conference.

Membership Categories

Annual Rate





  Associates (RN, PA, Surgical Techs)


  Resident/ Fellow


FEATURING Practice Discounts

3 practice members- ($1,000/year) $185 savings

5 Practice members- ($1,600/year)  $375 savings

7 practice members-  ($2,200/year)  $565 savings

OAS Members enjoy exclusive benefits:

Renew NOW

Member Opportunity

Take a survey for a chance to win $500 AMAZON Card

OAS President, Dr. Maggie Jeffries, recently published a paper regarding opiate use in cataract surgery. Below is a follow up survey she helped design to gain even more information to share with the ophthalmic anesthesia industry. Please take a few minutes to complete the survey, results will be shared later this year in a recap from Dr. Jeffries. A randomly selected winner will receive an electronic $250 Amazon Card. Be sure to fill out the survey for a chance to win!

Take the survey now

Topic: Recent FDA Warning to Enhance Patient Awareness of Unapproved Eye Treatments


Momin, Sibtainzehra MD MPH

Yerabolu, Krishin Undergraduate Student

Singh, Vinodkumar MD

University of Alabama at Birmingham

Birmingham VA Medical Center, Birmingham, AL


The U.S. Food and Drug Administration (FDA) has issued a stern warning indicating that eight companies are not in compliance with FDA regulations. This pertained to unapproved eye products being sold without adequate regulatory oversight. These products, which include various eye drops and ointments, pose a significant risk to consumers’ eye health. In this article, we will delve into this warning and why it’s crucial to be cautious while choosing eye products.

The FDA Warning:

In recent years, there has been a growing concern regarding the safety and efficacy of eye medications marketed to the common consumer. The FDA from time to time issues warning letters to inform the public of medications that could potentially harm instead of helping cure the problem at hand.

On September 12th, the FDA issued a letter stating that Boiron Inc., CVS Health, DR Vitamin Solutions, Natural Ophthalmics Inc., OcluMed LLC, Similasan AG/ Similasan USA, TRP Company Inc., and Walgreens Boots Alliance Inc. were all not in compliance with the regulations (Administration, 2023). Moreover, the FDA issued an urgent warning, emphasizing the vital need to remove all products linked to the claim within a strict 15 day timeframe. This pertains to a range of eye drops, ointments, and similar products that are being marketed and sold without the agency’s approval. The warning highlights several key concerns:

  • 1.      Lack of efficacy data: Unapproved eye products may not have undergone rigorous testing for efficacy, meaning there’s no guarantee they will work as intended.
  • 2.      Safety concerns: These products may contain ingredients that can cause irritation, allergies, or other adverse effects on the eyes, potentially leading to vision problems.
  • 3.      Quality control issues: Unregulated manufacturing processes can result in inconsistent product quality and contamination risks.
  • 4.      False claims: Some unapproved products make unfounded claims about their ability to treat various eye conditions, misleading consumers.

This poses a serious concern as the US Ophthalmic drug market continues to rise and individuals are put at risk every day due to drug companies not making medication safe to use (Figure 1).

Figure 1: Research done by Grand View research shows that the US Ophthalmic drug market continues to increase in market share. The jump from 2021 to 2022 shows a 113% percent increase and decade trajectories indicate the market share will continue to increase (Region, 2022).

Why the Warning Matters:

The human eye is a delicate organ, and using unapproved and potentially unsafe products can have serious consequences. For example, these eye drops/ointments may contain silver, and long-term usage of silver has been shown in literature reports to cause necrosis of conjunctival epithelia cells, argyria, irritation, corneal opacity, and symblepharon (Waszczykowska et al., 2021). It is imperative to understand that FDA approval is not a mere formality but a rigorous evaluation of products’ safety and efficacy. Unapproved products bypass this step, leaving consumers vulnerable to potentially harmful consequences. For this reason, the FDA has stated that legal action will be pursued if the claims are not addressed by the companies. FDA Director of Compliance Jill Furman ensures that the FDA continues to work hard to ensure that the unapproved eye medications are removed from the market to foster greater patient safety.

Protecting the Patients:

To safeguard your patients, consider:

  • 1.      Check FDA Approval: Always look for FDA approval on the packaging of any eye products that you dispense or use. If the certification is not present, exercise caution and skepticism.
  • 2.      Consult a Friend: Before prescribing or dispensing any new eye product, consult your reliable pharmacy or colleague. They can recommend safe or alternate options for your needs.
  • 3.      Report Suspected Issues: If you suspect any issues with the eye products, report it to the FDA’s MedWatch Program. This helps in monitoring and addressing safety concerns.
  • 4.      Be Skeptical of “Miracle” Claims: Beware of using products that promise beyond reason. If it sounds too good to be true, it probably is.


The well-being of both your patient's eyes and your own is invaluable and deserves utmost care and attention. Thisdecisive action by the FDA stands as an imperative component in elevating patient awareness of the harmful effects of unregulated treatments. By highlighting the violations, clarifying regulatory status, and promoting transparency, the FDA letter gives the public the information needed to make informed decisions about different treatment avenues for their eye conditions. As the industry continues to grow, the FDA needs to work to make sure patient safety is the highest priority to help avoid any unnecessary complications. Always trust in regulated and approved treatments, and always seek help and guidance when in doubt.


Administration, F. a. D. (2023). FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products. https://www.fda.gov/news-events/press-announcements/fda-issues-warning-letters-firms-marketing-unapproved-eye-products

Region, a. S. F. (2022). Ophthalmic Drugs Market Size, Share & Trends Analysis Report by Drug Class, by Disease (Dry Eye, Glaucoma), by Dosage Form, by Route of Administration, by Product Type (Prescription, OTC), by Region, and Segment Forecasts, 2022-2030. Retrieved September 29 from https://www.researchandmarkets.com/reports/4429696/ophthalmic-drugs-market-size-share-and-trends

Waszczykowska, A., Zyro, D., Ochocki, J., & Jurowski, P. (2021). Clinical Application and Efficacy of Silver Drug in Ophthalmology: A Literature Review and New Formulation of EYE Drops with Drug Silver (I) Complex of Metronidazole with Improved Dosage Form. Biomedicines, 9(2). https://doi.org/10.3390/biomedicines9020210

Copyright © 2023 Ophthalmic Anesthesia Society. All Rights Reserved.

Powered by Wild Apricot Membership Software